Reneo Pharmaceuticals Files 10-K/A Amendment

TL;DR

<b>Reneo Pharmaceuticals filed an amended 10-K for fiscal year 2023, confirming its Nasdaq listing and smaller reporting company status.</b>

AI Summary

Reneo Pharmaceuticals, Inc. (OKUR) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Reneo Pharmaceuticals, Inc. filed an amended 10-K report for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its IRS Employer Identification No. is 47-2309515. Its principal executive offices are located at 18575 Jamboree Road, Suite 275-S, Irvine, CA 92612. Reneo Pharmaceuticals' common stock is traded on The Nasdaq Stock Market LLC under the trading symbol RPHM. The filing indicates the company is a non-accelerated filer and a smaller reporting company.

Why It Matters

For investors and stakeholders tracking Reneo Pharmaceuticals, Inc., this filing contains several important signals. This amended filing provides updated information for the fiscal year 2023, which is crucial for investors to have the most current data on the company's status and operations. As a smaller reporting company and non-accelerated filer, Reneo Pharmaceuticals operates under specific regulatory requirements and disclosure expectations, impacting how its financial health and strategic direction are perceived by the market.

Risk Assessment

Risk Level: low — Reneo Pharmaceuticals, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, suggesting potential corrections or additions to previously reported information, but does not indicate significant new negative developments.

Analyst Insight

Monitor future filings for any material changes or updates stemming from this amendment.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported fiscal year end)
• 001-40315 — Commission File Number (SEC filing identifier)
• 47-2309515 — IRS Employer Identification No. (Tax identification number)
• RPHM — Trading Symbol (Nasdaq trading symbol)

Key Players & Entities

• Reneo Pharmaceuticals, Inc. (company) — Filer name
• 10-K/A (filing) — Form type
• December 31, 2023 (date) — Fiscal year end
• 001-40315 (filing) — Commission file number
• Delaware (jurisdiction) — State of incorporation
• 47-2309515 (identifier) — IRS Employer Identification No.
• 18575 Jamboree Road, Suite 275-S, Irvine CA 92612 (address) — Business address
• RPHM (ticker) — Trading Symbol

FAQ

Industry Context

Reneo Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing treatments for rare genetic metabolic diseases.

Regulatory Implications

The company is subject to standard SEC reporting requirements for publicly traded companies, including the filing of annual reports (10-K) and amendments.

What Investors Should Do

1. Review the full amended 10-K filing for any specific changes or new disclosures.
2. Monitor Reneo Pharmaceuticals' stock performance and future announcements.
3. Assess the company's financial health and strategic initiatives based on updated filings.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K/A filing.
• 2024-04-26: Filing Date — Date the amended 10-K was filed with the SEC.

Year-Over-Year Comparison

This is an amended 10-K filing for the fiscal year ended December 31, 2023, indicating updates or corrections to previously submitted information.

Key Financial Figures

• $0.0001 — ) on which registered Common Stock, $0.0001 Par Value per Share RPHM The Nasdaq
• $6.56 — Yes No Based on the closing price of $6.56 as reported on the Nasdaq Global Market

Filing Documents

• rphm-20231231.htm (10-K/A) — 718KB
• rphm-ex31_3.htm (EX-31.3) — 8KB
• rphm-ex31_4.htm (EX-31.4) — 7KB
• img27553928_0.jpg (GRAPHIC) — 10KB
• 0000950170-24-048631.txt (&nbsp;) — 1008KB
• rphm-20231231.xsd (EX-101.SCH) — 44KB
• rphm-20231231_htm.xml (XML) — 10KB

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 4

Executive Compensation

Item 11. Executive Compensation 9

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 17

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 19

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 21 PART IV

Exhibit and Financial Statement Schedules

Item 15. Exhibit and Financial Statement Schedules 23

Form 10-K Summary

Item 16. Form 10-K Summary 26

Signatures

Signatures 27 3 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance The following table sets forth information regarding our directors and executive officers as of March 31, 2024. There are no family relationships among any of our directors or executive officers. Director Name Age Position Directors Roshawn A. Blunt 49 Director Eric M. Dube, Ph.D. 51 Director Gregory J. Flesher 53 President and Chief Executive Officer, Director Michael Grey 71 Executive Chairman Paul W. Hoelscher 59 Director Edward T. Mathers 64 Director Bali Muralidhar, M.D., Ph.D. 44 Director Niall O'Donnell, Ph.D. 51 Director Stacey D. Seltzer 47 Director Executive Officers (other than Messrs. Flesher and Grey) Michael P. Cruse 52 Chief Operating Officer Alejandro Dorenbaum, M.D. 64 Chief Medical Officer Ashley F. Hall, J.D. 52 Chief Development Officer Directors Roshawn Blunt has served as a member of the Board of Directors (Board) since August 2022. Since August 2022, Ms. Blunt has served as President of Corsaire Corporation, a pharmaceutical commercialization organization. Previously, Ms. Blunt was the Founder and Managing Director of 1798, LLC (1798), a national health care consulting firm from September 2010 to June 2022. Prior to starting 1798, Ms. Blunt was Vice President of Strategy, Planning, and Communication at Long Beach Memorial Center and Miller Children's Hospital. She was the first Global Director of Health Economics and Reimbursement for Biosense Webster, Inc., a Johnson & Johnson company. Ms. Blunt also held a variety of strategic reimbursement and commercialization positions at Amgen, Inc. Ms. Blunt has been a member of the board of directors of Kronos Bio Inc., a public biopharmaceutical company, since November 2021. Ms. Blunt previously served on the board of directors of Adamis Pharmaceuticals Corporation, a public biopharmaceutical company, from August 2019 to September 2021. Ms. Blunt gradu

View Full Filing

View this 10-K/A filing on SEC EDGAR